Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Citi
Medtronic
Fish and Richardson
AstraZeneca
US Department of Justice
Baxter
Harvard Business School
Argus Health

Generated: November 17, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 204412

« Back to Dashboard

NDA 204412 describes DELZICOL, which is a drug marketed by Apil and is included in one NDA. It is available from two suppliers. There is one patent protecting this drug and one Paragraph IV challenge. Additional details are available on the DELZICOL profile page.

The generic ingredient in DELZICOL is mesalamine. There are twenty-eight drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the mesalamine profile page.
Summary for 204412
Tradename:DELZICOL
Applicant:Apil
Ingredient:mesalamine
Patents:1
Formulation / Manufacturing:see details
Pharmacology for NDA: 204412
Ingredient-typeAminosalicylic Acids
Medical Subject Heading (MeSH) Categories for 204412
Suppliers and Packaging for NDA: 204412
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
DELZICOL mesalamine CAPSULE, DELAYED RELEASE;ORAL 204412 NDA Allergan, Inc. 0023-5853 0023-5853-00 47300 CAPSULE, DELAYED RELEASE in 1 DRUM (0023-5853-00)
DELZICOL mesalamine CAPSULE, DELAYED RELEASE;ORAL 204412 NDA Allergan, Inc. 0023-5853 0023-5853-18 180 CAPSULE, DELAYED RELEASE in 1 BOTTLE (0023-5853-18)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE, DELAYED RELEASE;ORALStrength400MG
Approval Date:Feb 1, 2013TE:RLD:Yes
Patent:➤ Try a Free TrialPatent Expiration:Apr 13, 2020Product Flag?YSubstance Flag?Delist Request?

Expired US Patents for NDA 204412

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Apil DELZICOL mesalamine CAPSULE, DELAYED RELEASE;ORAL 204412-001 Feb 1, 2013 ➤ Try a Free Trial ➤ Try a Free Trial
Apil DELZICOL mesalamine CAPSULE, DELAYED RELEASE;ORAL 204412-001 Feb 1, 2013 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKinsey
AstraZeneca
Healthtrust
Queensland Health
Fuji
Accenture
Chubb
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.